Examining lung cancer patients (n = 65) with EGFR T790M who received 3rd generation EGFR-TKI, we find that the Kaplan-Meier curves for progression-free survival do not show significant differences between the low VAF cases (≤5%) and the high VAF cases (>5%) (Fig. 5e). The gene discussed is EGFR; the disease is lung carcinoma.